Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study.
Smithy JW, Kalvin HL, Ehrich FD, Shah R, Adamow M, Raber V, Maher CA, Kleman J, McIntyre DAG, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, Eton O, Nair S, Wolchok JD, Chapman PB, Berger MF, Panageas KS, Postow MA.
Smithy JW, et al. Among authors: nair s.
Clin Cancer Res. 2024 May 20. doi: 10.1158/1078-0432.CCR-23-3643. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38767650